公开(公告)号：US12121746B2

公开(公告)日：2024-10-22

申请号：US17433890

申请日：2020-01-30

申请人： IMMUNOLIGHT, LLC

发明人： Frederic A. Bourke, Jr. ,  Harold Walder ,  Zakaryae Fathi ,  Wayne F. Beyer ,  Ronald A. Rudder ,  Joseph H. Simmons

IPC分类号： A61N5/06 ,  A61K35/12 ,  A61K41/00 ,  A61N5/067 ,  C09J133/08 ,  C09K11/02 ,  C09K11/59 ,  C09K11/76 ,  C09K11/77 ,  C12N15/01 ,  F21K2/00 ,  F21S11/00 ,  F21V9/40 ,  H01J45/00 ,  H01L23/00 ,  H01L31/0352 ,  H01L31/054 ,  H01L31/06 ,  H01L31/055

CPC分类号： A61N5/0625 ,  A61K35/12 ,  A61K41/00 ,  A61K41/0057 ,  A61N5/0601 ,  A61N5/062 ,  A61N5/067 ,  C09J133/08 ,  C09K11/025 ,  C09K11/595 ,  C09K11/76 ,  C09K11/7701 ,  C09K11/7792 ,  C12N15/01 ,  F21K2/00 ,  F21S11/007 ,  F21V9/40 ,  H01J45/00 ,  H01L24/29 ,  H01L24/83 ,  H01L31/035281 ,  H01L31/054 ,  H01L31/06 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/0663 ,  H01L31/055 ,  H01L2224/2919 ,  H01L2224/29393 ,  H01L2224/8322 ,  H01L2224/83855

摘要： An emission enhancement structure having at least one energy augmentation structure; and an energy converter capable of receiving energy from an energy source, converting the energy and emitting therefrom a light of a different energy than the received energy. The energy converter is disposed in a vicinity of the at least one energy augmentation structure such that the emitted light is emitted with an intensity larger than if the converter were remote from the at least one energy augmentation structure. Also described are various uses for the energy emitters, energy augmentation structures and energy collectors in a wide array of fields, particularly medical uses for treatment of cell proliferation disorders.

公开(公告)号：US11998760B2

公开(公告)日：2024-06-04

申请号：US17433827

申请日：2020-02-27

申请人： IMMUNOLIGHT, LLC

发明人： Frederic A. Bourke, Jr. ,  Harold Walder ,  Zakaryae Fathi ,  Wayne F. Beyer ,  Ronald A. Rudder ,  Daniel I. Becker ,  Joseph H. Simmons

IPC分类号： H01L31/044 ,  A61K35/12 ,  A61K41/00 ,  A61N5/06 ,  A61N5/067 ,  C09J133/08 ,  C09K11/02 ,  C09K11/59 ,  C09K11/76 ,  C09K11/77 ,  C12N15/01 ,  F21K2/00 ,  F21S11/00 ,  F21V9/40 ,  H01J45/00 ,  H01L23/00 ,  H01L31/0352 ,  H01L31/054 ,  H01L31/06 ,  H01L31/055

CPC分类号： A61N5/0625 ,  A61K35/12 ,  A61K41/00 ,  A61K41/0057 ,  A61N5/0601 ,  A61N5/062 ,  A61N5/067 ,  C09J133/08 ,  C09K11/025 ,  C09K11/595 ,  C09K11/76 ,  C09K11/7701 ,  C09K11/7792 ,  C12N15/01 ,  F21K2/00 ,  F21S11/007 ,  F21V9/40 ,  H01J45/00 ,  H01L24/29 ,  H01L24/83 ,  H01L31/035281 ,  H01L31/054 ,  H01L31/06 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/0663 ,  H01L31/055 ,  H01L2224/2919 ,  H01L2224/29393 ,  H01L2224/8322 ,  H01L2224/83855

摘要： An emission enhancement structure having at least one energy augmentation structure; and an energy converter capable of receiving energy from an energy source, converting the energy and emitting therefrom a light of a different energy than the received energy. The energy converter is disposed in a vicinity of the at least one energy augmentation structure such that the emitted light is emitted with an intensity larger than if the converter were remote from the at least one energy augmentation structure. Also described are various uses for the energy emitters, energy augmentation structures and energy collectors in a wide array of fields, especially in the field of solar cells and other energy conversion devices.

公开(公告)号：US11964166B2

公开(公告)日：2024-04-23

申请号：US17433734

申请日：2020-02-27

申请人： IMMUNOLIGHT, LLC

发明人： Frederic A Bourke, Jr. ,  Harold Walder ,  Zakaryae Fathi ,  Wayne F. Beyer ,  Ronald A. Rudder ,  Joseph H. Simmons

IPC分类号： A61N5/06 ,  A61K35/12 ,  A61K41/00 ,  A61N5/067 ,  C09J133/08 ,  C09K11/02 ,  C09K11/59 ,  C09K11/76 ,  C09K11/77 ,  C12N15/01 ,  F21K2/00 ,  F21S11/00 ,  F21V9/40 ,  H01J45/00 ,  H01L23/00 ,  H01L31/0352 ,  H01L31/054 ,  H01L31/06 ,  H01L31/055

CPC分类号： A61N5/0625 ,  A61K35/12 ,  A61K41/00 ,  A61K41/0057 ,  A61N5/0601 ,  A61N5/062 ,  A61N5/067 ,  C09J133/08 ,  C09K11/025 ,  C09K11/595 ,  C09K11/76 ,  C09K11/7701 ,  C09K11/7792 ,  C12N15/01 ,  F21K2/00 ,  F21S11/007 ,  F21V9/40 ,  H01J45/00 ,  H01L24/29 ,  H01L24/83 ,  H01L31/035281 ,  H01L31/054 ,  H01L31/06 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/0663 ,  H01L31/055 ,  H01L2224/2919 ,  H01L2224/29393 ,  H01L2224/8322 ,  H01L2224/83855

摘要： An emission enhancement structure having at least one energy augmentation structure; and an energy converter capable of receiving energy from an energy source, converting the energy and emitting therefrom a light of a different energy than the received energy. The energy converter is disposed in a vicinity of the at least one energy augmentation structure such that the emitted light is emitted with an intensity larger than if the converter were remote from the at least one energy augmentation structure. Also described are various uses for the energy emitters, energy augmentation structures and energy collectors in a wide array of fields, including various adhesives applications.

公开(公告)号：US20240042233A1

公开(公告)日：2024-02-08

申请号：US18360187

申请日：2023-07-27

申请人： Immunolight, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER, JR. ,  Mark DEWHIRST ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61N5/06 ,  A61K41/17 ,  A61K39/00 ,  A61K41/00 ,  A61K49/04 ,  A61N5/02 ,  A61N5/10

CPC分类号： A61N5/062 ,  A61K41/17 ,  A61K39/0011 ,  A61K41/0066 ,  A61K49/0423 ,  A61N5/022 ,  A61N5/10 ,  A61N5/1081 ,  A61K2039/585 ,  A61N2005/0627 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1089 ,  A61N2005/1098

摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

公开(公告)号：US11865359B2

公开(公告)日：2024-01-09

申请号：US16728803

申请日：2019-12-27

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Harold Walder ,  Frederic A. Bourke, Jr. ,  Zakaryae Fathi ,  Wayne F. Beyer, Jr. ,  Mark Dewhirst ,  Mark Oldham ,  Justus Adamson ,  Michael Nolan

IPC分类号： A61N5/06 ,  A61K41/17 ,  A61K39/00 ,  A61K41/00 ,  A61K49/04 ,  A61N5/02 ,  A61N5/10

CPC分类号： A61N5/062 ,  A61K39/0011 ,  A61K41/0066 ,  A61K41/17 ,  A61K49/0423 ,  A61N5/022 ,  A61N5/10 ,  A61N5/1081 ,  A61K2039/585 ,  A61N2005/0627 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1089 ,  A61N2005/1098

摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

公开(公告)号：US11577092B2

公开(公告)日：2023-02-14

申请号：US16322178

申请日：2017-08-01

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold Walder ,  Frederic A. Bourke, Jr. ,  Zakaryae Fathi ,  Wayne Beyer ,  Mark Oldham ,  Justus Adamson ,  Paul Yoon

IPC分类号： A61K9/00 ,  A61N5/06 ,  A61N5/10 ,  A61K41/00 ,  A61K33/42 ,  A61P35/00

摘要： A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.

公开(公告)号：US11571587B2

公开(公告)日：2023-02-07

申请号：US16860623

申请日：2020-04-28

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Frederic A. Bourke, Jr. ,  Harold Walder ,  Zakaryae Fathi ,  Michael J. Therien ,  Mark W. Dewhirst ,  Ian N. Stanton ,  Jennifer Ann Ayres ,  Diane Renee Fels ,  Joseph A. Herbert

IPC分类号： A61N5/06 ,  A61K41/00 ,  A61N5/10

摘要： A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.

公开(公告)号：US11534622B2

公开(公告)日：2022-12-27

申请号：US15504917

申请日：2015-08-17

申请人： IMMUNOLIGHT, LLC

发明人： Frederic A. Bourke, Jr. ,  Zakaryae Fathi ,  Harold Walder

IPC分类号： A61N5/06 ,  A61B18/00 ,  A61B18/18 ,  B82Y30/00 ,  A61N1/40 ,  A61N5/02 ,  A61N5/10 ,  A61N5/067

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US20220159998A1

公开(公告)日：2022-05-26

申请号：US17650997

申请日：2022-02-14

申请人： IMMUNOLIGHT, LLC

发明人： Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Harold WALDER ,  Wayne F. BEYER, JR.

IPC分类号： A23L3/28 ,  A23L3/26 ,  A61L2/08 ,  A61M1/36 ,  C02F1/32 ,  G03F7/20 ,  A61N5/06 ,  A61L2/00 ,  A61M1/34 ,  C23C16/458

摘要： A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

公开(公告)号：US11305131B2

公开(公告)日：2022-04-19

申请号：US16554831

申请日：2019-08-29

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Mark Oldham ,  Zakaryae Fathi ,  Wayne F. Beyer ,  Frederic A. Bourke, Jr. ,  Harold Walder ,  Mark DeWhirst ,  Neil L. Spector ,  Paul Yoon ,  Justus Adamson ,  David Alcorta ,  Kim Lyerly ,  Leihua Liu ,  Takuya Osada

IPC分类号： A61N5/06 ,  A61K41/00 ,  A61N5/10 ,  A61K31/352

摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.